An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson’s disease

Brain Structure and Function

Volumn 220, Issue 1, 2015, Pages 479-500

  Pienaar, Ilse S ^a   Harrison, Ian F ^a   Elson, Joanna L ^b,c   Bury, Alexander ^a   Woll, Petter ^d   Simon, Anna Katharina ^d   Dexter, David T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NORTH WEST UNIVERSITY   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cholinergic neurons; Neurodegeneration; Parkinson s disease; Pedunculopontine nucleus; Proteasomal inhibitor

Indexed keywords

ACETYLCYSTEINE; CALCIUM BINDING PROTEIN; CHOLINE ACETYLTRANSFERASE; CYSTEINE PROTEINASE INHIBITOR; ENOLASE; LACTACYSTIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MUSCLE PROTEIN; OX-6 MONOCLONAL ANTIBODY; SYNTROPHIN ALPHA1; TYROSINE 3 MONOOXYGENASE;

ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; CELL COUNT; CHOLINERGIC NERVE CELL; COMPLICATION; DISEASE MODEL; FORELIMB; HEMISPHERIC DOMINANCE; IMAGE PROCESSING; LASER CAPTURE MICRODISSECTION; MALE; METABOLISM; MOTOR ACTIVITY; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; RAT; SPRAGUE DAWLEY RAT;

ACETYLCYSTEINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; CALCIUM-BINDING PROTEINS; CELL COUNT; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC NEURONS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FORELIMB; FUNCTIONAL LATERALITY; IMAGE PROCESSING, COMPUTER-ASSISTED; LASER CAPTURE MICRODISSECTION; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE PROTEINS; MOTOR ACTIVITY; MUSCLE PROTEINS; NERVE DEGENERATION; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PHOSPHOPYRUVATE HYDRATASE; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 84922428157     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-013-0669-5     Document Type: Article

References (90)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329. doi:10.1046/j.1471-4159.1997.69031326.x
2. Alessandro S, Ceravolo R, Brusa L, Pierantozzi M, Costa A, Galati S, Placidi F, Romigi A et al (2010) Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J Neurol Sci 289:44–48. doi:10.1016/j.jns.2009.08.017
3. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M (1993) T2 relaxation time in patients with Parkinson’s disease. Neurology 43:697. doi:10.1212/WNL.43.4.697
4. Bandhyopadhyay U, Cuervo AM (2007) Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein. Exp Gerontol 42:120–128. doi:10.1016/j.exger.2006.05.019
5. Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of modelbased (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161:1082–1090. doi:10.1016/j.neuroscience.2009.04.031
6. Baskerville KA, Kent C, Personett D, Lai WR, Park PJ, Coleman P, Mckinney M (2008) Aging elevates metabolic gene expression in brain cholinergic neurons. Neurobiol Aging 29:1874–1893. doi:10.1016/j.neurobiolaging.2007.04.024
7. Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221:564–573. doi:10.1016/j.bbr.2009.12.048
8. Brar S, Henderson D, Schenck J, Zimmerman E (2009) Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch Neurol 66:371–374. doi:10.1001/archneurol.2008.586
9. Bursch W (2001) The autophagosomal–lysosomal compartment in programmed cell death. Cell Death Differ 8:569–581. doi:10.1038/sj.cdd.4400852
10. Butler D, Nixon RA, Bahr BA (2006) Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy 2:234–237
11. Chen J, Hardy P, Kucharczyk W, Clauberg M, Joshi J, Vourlas A, Dhar M, Henkelman RM (1993) MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 14:275–281
12. Cho BP, Song DY, Sugama S, Shin DH, Shimizu Y, Kim SS, Kim YS, Joh TH (2006) Pathological dynamic of activated microglia following medial forebrain bundle transection. Glia 53:92–102. doi:10.1002/glia.20265
13. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79–86. doi:10.1038/nrm1552
14. Cook C, Petrucelli L (2009) A critical evaluation of the ubiquitin proteasome system in Parkinson’s disease. Biochim Biophys Acta 1792:664–675. doi:10.1016/j.bbadis.2009.01.012
15. Dexter DT, Wells FR, Lee AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836. doi:10.1111/j.1471-4159.1989.tb07264.x
16. Dickson DW (2007) Linking selective vulnerability to cell death mechanisms in Parkinson’s disease. Am J Pathol 170:16–19. doi:10.2353/ajpath.2007.061011
17. Dugger BN, Murray ME, Boeve BF, Parisi JE, Benarroch EE, Ferman TJ, Dickson DW (2012) Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to REM sleep behaviour disorder. Neuropathol Appl Neurobiol 38:142–152. doi:10.1111/j.1365-2990.2011.01203
18. Ferraye MU, Debû B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E et al (2010) Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 133:205–214. doi:10.1093/brain/awp229
19. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K et al (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164. doi:10.1038/ncb748
20. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985–989. doi:10.1126/science.290.5493.985
21. Gorell JM, Ordidge RJ, Brown GG, Deniau J-C, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45:1138–1143. doi:10.1212/WNL.45.6.1138
22. Gundersen HJG (1977) Notes on the estimation of the numerical density of arbitrary particles. J Microsc 111:219–223
23. Halliday GM (2009) Thalamic changes in Parkinson’s disease. Parkinsonism Relat Disord 15:S152–S155. doi:10.1016/S1353-8020(09)70804-1
24. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2012) A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study. J Neurosci Methods 2010:187–194. doi:10.1016/j.jneumeth.2012.07.013
25. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84:5976–5980
26. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoiola F, Tolosa E (2006) Rapid-eye movement sleep behaviour disorder as an early marker for neurodegenerative disorder: a descriptive study. Lancet Neurol 5:572–577. doi:10.1016/S1474-4422(06)70476-8
27. Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ (2004) Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. NeuroReport 15:2621–2624
28. Jenkinson N, Nandi D, Oram R, Stein JF, Aziz TZ (2006) Pedunculopontine nucleus electric stimulation alleviates akinesia independently of dopaminergic mechanisms. NeuroReport 17:639–641
29. Karachi C, Grabli D, Bernard FA, Tandé D, Wattiez N, Belaid H, Bardinet E, Prigent A et al (2010) Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120:1026–1033. doi:10.1172/JCI42642
30. Kaur C, Ling EA (1992) Activation and re-expression of surface antigen in microglia following an epidural application of kainic acid in the rat brain. J Anat 180:333–342
31. Kondoh T, Bannai M, Nishino H, Torii K (2005) 6-Hydroxydopamine induced lesions in a rat model of hemi-Parkinson’s disease monitored by magnetic resonance imaging. Exp Neurol 192:194–202. doi:10.1016/j.expneurol.2004.12.016
32. Kosta P, Argyropoulou M, Markoula S, Konitsiotis S (2006) MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease. J Neurol 253:26–32. doi:10.1007/s00415-005-0914-9
33. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312–318
34. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 75:345–353
35. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408. doi:10.1006/meth 2001.1262
36. Lorenc-Koci E, Lenda T, Antkiewicz-Michaluk L, Wardas J, Domin H, Smiałowska M, Konieczny J (2011) Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson’s disease in rats. Neurochem Internat 58:839–849. doi:10.1016/j.neuint.2011.03.013
37. Lue L-F, Kuo Y-M, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 41:115–128. doi:10.1007/s12035-010-8106-8
38. MacInnes N, Iravani MM, Perry E, Piggott M, Perry R, Jenner P, Ballard C (2008) Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm 115:869–878. doi:10.1007/s00702-008-0027-6
39. Mackey S, Jing Y, Flores J, Dinelle K, Doudet DJ (2013) Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behaviour, positron emission tomography, immunohistochemistry. Exp Neurol 247:19–24. doi:10.1016/j.expneurol.2013.03.021
40. Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y (2000) Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci USA 97:9487–9492. doi:10.1073/pnas.140216197
41. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem 110:966–975. doi:10.1111/j.1471-4159.2009.06189.x
42. Martinez-Vicente M, Cuervo AM (2007) Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 6:352–361. doi:10.1016/S1474-4422(07)70076-5
43. Maskos U (2008) The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology. Br J Pharmacol 153:S438–S445. doi:10.1038/bjp.2008.5
44. McCarley RW (2007) Neurobiology of REM and NREM sleep. Sleep Med 8:302–330. doi:10.1016/j.sleep.2007.03.005
45. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin–proteasome system in Parkinson’s disease. Nat Rev Neurosci 2:589–594. doi:10.1038/35086067
46. McNaught KSP, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Oleo CW (2002) Impairment of the ubiquitin–proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301–306. doi:10.1046/j.1471-4159.2002.00821.x
47. Mena-Segovia J, Micklem BR, Nair-Roberts RG, Ungless MA, Bolam JP (2009) GABAergic neuron distribution in the pedunculopontine nucleus defines functional subterritories. J Comp Neurol 515:397–408. doi:10.1002/cne.22065
48. Menke RA, Scholz J, Miller KL, Deoni S, Jbabdi S, Matthews PM, Zarei M (2009) MRI characteristics of the substantia nigra in Parkinson’s disease: a combined quantitative T1 and DTI study. NeuroImage 47:435–441. doi:10.1016/j.neuroimage.2009.05.017
49. Mesulam MM, Mufson EJ, Wainer BH, Levey AI (1983) Central cholinergic pathways in the rat: an overview based on alternative nomenclature (Hh1-Ch6). Neuroscience 10:1185–1201
50. Miletich RS, Bankiewicz KS, Quarantelli M, Plunkett RJ, Frank J, Kopin IJ, Di Chiro G (1994) MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Ann Neurol 35:689–697
51. Moro E, Hamani C, Poon YY, Al-Khairallah T, Dostrovsky JO, Hutchison WD, Lozano AM (2010) Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain 133:215–224. doi:10.1093/brain/awp261
52. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318. doi:10.1126/science.1110647
53. Niu C, Mei J, Pan Q, Fu X (2009) Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact Funct Neurosurg 87:69–81. doi:10.1159/000202972
54. Olanow CW, McNaught KS (2006) Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 21:1806–1823. doi:10.1002/mds.21013
55. Oorschot DE (1998) Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical dissector methods. J Compar Neurol 366:580–599. doi:10.1002/(SICI)1096-986119960318
56. Ossig C, Reichmann H (2013) Treatment of Parkinson’s disease in the advanced stage. J Neural Transm. doi:10.1007/s00702-013-1008-y (in press)
57. Paine SML, Anderson G, Bedford K, Lawler K, Mayer RJ, Lowe J, Bedford L (2013) Pale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of α-synuclein. PLoS One 8:e54711. doi:10.1371/journal.pone.0054711
58. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
59. Paxinos G, Watson C (2009) The rat brain in stereotaxic coordinates. Academic Press, Sydney
60. Péran P, Nemmi F, Méligne D, Cardebat D, Peppe A, Rascol O, Caltagirone C, Demonet JF et al (2012) Effect of levodopa on both verbal and motor representations of action in Parkinson’s disease: a fMRI study. Brain Lang 125:324–329. doi:10.1016/j.bandl.2012.06.001
61. Petersen MA, Dailey ME (2004) Diverse microglial motility behaviors during clearance of dead cells in hippocampal slices. Glia 46:195–206. doi:10.1002/glia.10362
62. Pienaar IS, Van de Berg W (2013) A non-cholinergic neuronal loss in the pedunculopontine nucleus of toxin-evoked Parkinsonian rats. Exp Neurol 248C:213–223. doi:10.1016/j.expneurol.2013.06.008
63. Pienaar IS, Kellaway LA, Russell VA, Stein DJ, Zigmond MJ, Daniels WMU (2007) Maternal separation exaggerates the toxic effects of 6-OHDA in adult rats: implications for neurodegenerative disorders. Stress 11:448–456. doi:10.1080/10253890801890721
64. Pienaar IS, Elson JL, Racca C, Nelson G, Turnbull DM, Morris CM (2013) Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson’s disease. Am J Pathol. pii:S0003-9440(13)00609-3 (in press)
65. Plaha P, Gill SS (2005) Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. NeuroReport 16:1883–1887
66. Platt B, Riedel G (2011) The cholinergic system, EEG and sleep. Behav Brain Res 221:299–504. doi:10.1016/j.bbr.2011.01.017
67. Rideout HJ, Larsen KE, Sulzer D, Stefanis L (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78:899–908. doi:10.1046/j.1471-4159.2001.00474.x
68. Rinne JO, Ma SY, Lee MS, Collan Y, Röyttä M (2008) Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients. Parkinsonism Relat Disord 14:553–557. doi:10.1016/j.parkreldis.2008.01.006
69. Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B, Burn DJ (2012) Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain 135:2779–2788. doi:10.1093/brain/aws207
70. Rodriguez-Pallares J, Parga JA, Munoz A, Rey P, Guerra MJ, Labandeira-Garcia JL (2007) Mechanism of 6-hydroxydopamine neurotoxicity: role of NADPH oxidase and microglial activation in 6-hydroxydopamine induced degeneration of dopaminergic neurons. J Neurochem 103:145–156. doi:10.1111/j.1471-4159.2007.04699.x
71. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443:780–786. doi:10.1038/nature05291
72. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacol 39:777–787. doi:10.1016/s0028-3908(00)00005-8
73. Schenck CH, Bundie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38 % of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46:388–393. doi:10.1212/WNL.46.2.388
74. Schmitz C, Hof PR (2005) Design-based stereology in neuroscience. Neuroscience 130:813–831. doi:10.1016/j.neuroscience.2004.08.050
75. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
76. Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L et al (2007) Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 130:1596–15607. doi:10.1093/brain/awl346
77. Streit WJ, Kreutzberg GW (1988) Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin. J Comp Neurol 268:248–263
78. Vernon AC, Johansson SM, Modo MM (2010) Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s disease. BMC Neurosci 11:1471–2202. doi:10.1186/1471-2202-11-1
79. Vernon AC, Crum WR, Johansson SM, Modo M (2011) Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson’s disease. PLoS One 6:e17269. doi:10.1371/journal.pone.0017269
80. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211:489–495
81. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J (2009) Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29:3974–3980. doi:10.1523/JNEUROSCI.4363-08.2009
82. West MJ (1993) New stereological methods for counting neurons. Neurobiol Aging 14:275–285
83. West MJ, Gundersen HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296:1–22
84. Wolf OT, Dyakin V, Vadasz C, de Leon MJ, McEwen BS, Bulloch K (2002) Volumetric measurement of the hippocampus, the anterior cingulate cortex, and the retrosplenial granular cortex of the rat using structural MRI. Brain Res Brain Res Protoc 10:41–46. doi:10.1016/S1385-299X(02)00181-2
85. Wong E, Cuervo AM (2010) Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 13:805–811. doi:10.1038/nn.2575
86. ® TaqMan 48 Analyzer using RNA extracted from formalin-fixed paraffin embedded tissue. First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12–15. Abstract number: A11
87. Wyllie AH, Kerr JF, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68:251–306
88. Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord 26:2496–2503. doi:10.1002/mds.23932
89. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB et al (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835–3844. doi:10.1096/fj.07-8386com
90. Zrinzo L, Zrinzo LV (2008) Surgical anatomy of the pedunculopontine and peripeduncular nuclei. Br J Neurosurg 22:S19–S24. doi:10.1080/02688690802448426